USPTO 2015–2025 USPTO PatentsView US Corporation

CHEMOCENTRYX, INC.

USPTO PatentsView assignee record — 135 granted patents across 11 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

135
Total patents granted
11
CPC technology areas
18.3
Avg claims per patent
+76%
5-year filing velocity

The verdict

CHEMOCENTRYX holds 135 US patents across 11 technology areas — rank #2,836 of 50,000 tracked assignees.

#2,836
of 50,000 US assignees by volume
Top 23%
by Innovation Score (45.6/100)
18.3
avg claims per patent
+76%
filing velocity, last 5 yrs

Portfolio overview

CHEMOCENTRYX, INC. has been granted 135 US utility patents between 2015 and 2025, placing CHEMOCENTRYX, INC. at rank #2,836 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, CHEMOCENTRYX, INC. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 45.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 86 grants, compared with 49 in the 2015–2019 window — a +76% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. CHEMOCENTRYX, INC.'s 18.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark CHEMOCENTRYX, INC. against peers pursuing similar technology classes.

How does CHEMOCENTRYX compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows CHEMOCENTRYX holds 135 patents — placing it at rank #2,836 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

CHEMOCENTRYX's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

46 Top 23% higher than 77% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

0510152025 20152016201720182019202020212022202320242025 3
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
CHEMOCENTRYX, INC. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 8 5.9%
2016 7 5.2%
2017 13 9.6%
2018 4 3.0%
2019 17 12.6%
2020 20 14.8%
2021 16 11.9%
2022 18 13.3%
2023 17 12.6%
2024 12 8.9%
2025 3 2.2%

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating

Where it ranks

Overall rank by patents

#2,836

Across all tracked assignees

Innovation Score

45.6 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does CHEMOCENTRYX, INC. hold?
CHEMOCENTRYX, INC. holds 135 US granted patents filed between 2015 and 2025, spanning 11 technology areas.
What is CHEMOCENTRYX, INC.'s Innovation Score?
CHEMOCENTRYX, INC. has an Innovation Score of 45.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does CHEMOCENTRYX, INC. focus on?
CHEMOCENTRYX, INC.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 124 patents. The company has filed patents in 11 CPC subclasses total.
Is CHEMOCENTRYX, INC.'s patent filing rate increasing or decreasing?
CHEMOCENTRYX, INC.'s recent filing velocity is +76% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for CHEMOCENTRYX, INC.'s patents?
CHEMOCENTRYX, INC.'s patents average 18.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the CHEMOCENTRYX, INC. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope